Radiopharmaceutical Producer Orders 12 Production Systems
The 12-system deployment scales PET tracer output for a U.S. national network to meet rising patient demand.
Updated on Oct. 15, 2026 in Manufacturing
Live Poll
Should healthcare manufacturers prioritize building excess production capacity ahead of patient demand?
IBA secured a contract to supply 12 Cyclone KIUBE 300 systems to a radiopharmaceutical producer for a new national production network in the United States. The deal includes facility design, equipment installation, and staff training to scale high-volume PET tracer production.
Why it matters
Radiopharmaceutical producers are scaling infrastructure to overcome industrial capacity constraints, signaling a shift toward higher-volume commercial production to meet anticipated patient demand. For operators in the medical supply sector, this highlights the necessity of robust, high-uptime equipment to support national distribution networks.
IBA will provide 12 Cyclone KIUBE 300 systems, each capable of producing 35 Ci of 18F in two hours. These units, which cost between 2.5 and 5 million euros each, are designed to maintain fleet uptime exceeding 97 percent for commercial producers.
The players
IBA
A Belgium-based company specializing in particle accelerator technology with 2,300 employees worldwide.
The details
The Cyclone KIUBE 300 systems use multiple Nirta HCFT 18F helium cooling free targets to facilitate high-volume PET tracer output. By integrating facility design and commissioning into the contract, the manufacturer provides an end-to-end operational setup that allows the buyer to expand into both fluorine-18 production and future radiometal applications. The configuration is specifically engineered to handle high throughput, a critical requirement for scaling national medical supply chains.
Timeline
October 15, 2026: IBA announced the contract order.
Market Landscape
This deal underscores the industry-wide move toward industrial-scale PET tracer production using the Cyclone KIUBE 300 system platform. It reflects a broader trend of centralized radiopharmaceutical producers investing heavily in automated, high-uptime manufacturing to secure supply-side reliability.
Operators in the medical manufacturing space should monitor how this 12-system deployment affects domestic PET tracer availability in the coming years. Facilities planning for future capacity should evaluate whether their equipment provides the 97 percent uptime benchmarks currently demanded by national production networks.
The takeaway
Commercial radiopharmaceutical production relies on high-uptime infrastructure to prevent supply gaps in national distribution models. Operators should track the commissioning timelines of these 12 systems as a bellwether for increased tracer availability and potential competitive pricing shifts in the PET market.
Further reading
For more on industry infrastructure trends, visit the Manufacturing section.
More information
Find further details on the company's technology at the IBA corporate information website.
Live Poll
Should healthcare manufacturers prioritize building excess production capacity ahead of patient demand?
